Kornimate/medical-research-clean huggingface dataset:
pelvic floor muscle training to treat urinary incontinence after radical prostatectomy

Conditions: Urinary Incontinence

Summary: the aim of this study is to evaluate the effect of pelvic floor muscle training in the treatment of urinary incontinence after radical prostatectomy.

urinary incontinence is a well known side effect of radical prostatectomy. the prevalence differs according to time period after the operation and the definition of incontinence used. however, a prevalence of 10-20% have been reported one year after the operation. pelvic floor muscle training has been suggested as a treatment of urinary incontinence. the aim of this study is to evaluate the effect of pelvic floor muscle training in the treatment of urinary incontinence after radical prostatectomy.we conduct a randomized clinical trial, comparing one group(n=40) following a pelvic floor muscle training program after prostatectomy and one group (n=40) receiving only standard information.primary outcome variable is self registration of urinary incontinence.

Eligibility criteria:
inclusion criteria: * cancer prostata operated (radical prostatectomy) * incontinence after separation of catheter * understands norwegian language exclusion criteria: * drug/alcohol abuse

Keywords: urinary incontinence pelvic floor muscle training radical prostatectomy physiotherapy
habits, orthorexia nervosa and lifestyle in students

Conditions: Habits; Health Behavior; Diet Habit; Sleep; Stress; Physical Activity

Summary: non-communicable diseases (ncds) compose a substantial proportion of the global burden of diseases, posing a significant challenge in both high-income and low- and middle-income countries. in particular, certain lifestyle-related risk factors, such as unhealthy diet, physical inactivity, smoking, excessive alcohol consumption, and sleep deprivation are the leading risk factors, which place people at an increased risk of developing ncds. on the other hand, a growing phenomenon of excessive concern about diet and health is emerging, and it is contributing to the development of a novel eating behavior disorder named orthorexia nervosa. according to recent studies, orthorexic behavior is very common among young adults and especially so in health-care professionals. the main objective of this multi-center study is to explore and compare lifestyle habits among undergraduate medical students and other healthcare-related professions from different countries (croatia, lebanon, italy, poland, spain, and turkey). the goal is to obtain information on the presence of unhealthy habits in order to be able to intervene, offering the information needed for primordial disease prevention in this young and still healthy group of respondents, who are the health educators and role models of the future. the particular importance of this goal is to raise awareness of the problem of the ubiquitously present unhealthy lifestyles. unfortunately, health-care students are not the exception regarding the prevalence of the unhealthy diet, sedentary behavior, sleep deprivation and high levels of psychological stress. furthermore, the adoption of unhealthy lifestyle patterns in health-care workers, such as doctors and nurses, will have far-reaching negative consequences, in both their health and their patients' health. the results of this study will be used for identifying the needs and targets for intervention, enabling students to become a pillar of health education for their patients and the population in general.


Eligibility criteria:
inclusion criteria: 1. students enrolled in any of the health-care related studies: * medical students * dental medicine students * pharmacy students * nursing students * physiotherapy students * dietetics/nutrition students * biomolecular science students * biomedical laboratory techniques students * psychology students 2. economy students 3. students of maritime sciences exclusion criteria: * none

Keywords: mediterranean diet physical activity sleep stress orthorexia nervosa
a study evaluating the pharmacokinetics of three qrl-101 formulations in healthy participants

Conditions: Healthy Volunteers

Summary: this study aims to evaluate the pharmacokinetics of three qrl-101 formulations in a fasted condition or in the presence of a high-fat meal in healthy participants.

this is a randomized, open-label, single-dose, crossover study to evaluate the pk of three formulations of qrl-101 beginning in a fasted condition before moving to a fed cross-over design. approximately 24 healthy participants will be enrolled in a 3-formulation, 4-period, 6-sequence crossover study design to evaluate the pk characteristics of three formulations of qrl-101.

Eligibility criteria:
inclusion criteria: 1. age 18 to 70 years of age inclusive at the time of signing the informed consent. 2. clinical chemistry laboratory values within acceptable range for the population, as per investigator judgment. 3. body mass index of 18 to 32 kg/m2 (inclusive). 4. willing and able to practice effective contraception. exclusion criteria: 1. currently enrolled in any other clinical trial involving a study drug or off-label use of a drug or device, or any other type of medical research judged not to be scientifically or medically compatible with this study. 2. any participant in \>4 studies a year and/or has participated in a clinical trial within 1 month of the expected dosing date. 3. history or presence of medical illness including, but not limited to, any cardiovascular, hepatic, respiratory, hematological, endocrine, psychiatric, or neurological disease, convulsions, or any clinically significant laboratory abnormality that, in the judgment of the investigator, indicate a medical problem that would preclude study participation.

Keywords: healthy volunteers
prostate localization during radiotherapy using a ni-ti stent and electronic portal imaging - protocol ii

Conditions: Prostatic Neoplasms

Summary: a new method for localization of the prostate during external beam radiotherapy. the method is based on insertion of a new thermo-expandable ni-ti stent. the radiological properties of the stent are used for precise prostate localization during treatment using electronic portal images

inclusion criteria's in the study were 1) patients should present with histological verified local or locally advanced pc (stage t2b to t3b, n0, m0; uicc 1992 classification was used). 2) patients should consequently be candidates for intended curative radiotherapy. prostatic work up is done before inclusion in the study. a new prostatic nickel - titanium stent is placed in the prostatic urethra one week prior to the radiotherapy planning ct using a flexible cystoscope to insert the stent under urethral anaesthesia. the stent is then flushed with hot water (60 degrees celsius). the hot water expands the stent collar, thereby locking the stent in place. correct positioning of the stent is secured visually on retraction of the scope. radiotherapy of prostate is given to a mean dose of 70 (department standard regime). treatment are given with daily fractions of 2 gy using a combination of 6 mv and 18 mv x-ray fields using isocentric 3d conformal treatment plan, consisting of three mlc conformal radiation fields (one anterior and two lateral wedged fields). this was assumed to be the optimal treatment plan. a pair of orthogonal 15 cm x 15 cm isocenter setup fields was added to the plan. the orthogonal fields are used to obtain pairs of electronic portal images. electronic portal images are recorded using a varian as500 electronic portal imaging device (epid). the images are used to determine the 3d reference position of the stent. the image pairs of the stent were taken at eight treatment sessions in each patient (session number 1,2,3,6,11,21,22 and 23). from each orthogonal set of images the 3d position of both the stent and the symphysis (pubic bone) are determined. positions are calculated using orthogonal reconstruction. a control ct scan is made before treatment session number 21 to verify the intra prostatic position of the stent. the intra prostatic position of the stent is also verified during removal of the stent three months after radiation therapy. before removal the stent was flushed with water at 10 degrees celsius. when cooled with 10°c cold water, the stent became super soft, and can easily be removed as a twisted wire.

Eligibility criteria:
inclusion criteria: 1. patients should present with histological verified local or locally advanced pc (stage t2b to t3b, n0, m0; uicc 1992 classification was used). 2. patients should consequently be candidates for intended curative radiotherapy - exclusion criteria: dislocation or removal of stent

Keywords: radiotherapy image guided marker
evaluation of the efficacy for sentinel lymph node policy in intermediate-risk endometrial carcinomas

Conditions: Endometrial Endometrioid Adenocarcinoma

Summary: to evaluate the efficacy of sentinel lymph node policy in patients with intermediate-risk endometrial carcinomas

surgical assessment for staging of endometrial carcinoma during primary surgery remains one of the most varied practices worldwide, as it may include no nodal assessment, sentinel node mapping, and complete pelvic and aortic lymphadenectomy up to the renal vessels. since lymphadenectomy is significantly associated with longer operating time, higher surgical costs, greater rate of infection, as well as the occurrence of lymphocysts and lymphedema, gynecologists agree that pelvic and aortic lymphadenectomy should be routinely performed in high-risk patients (grade 3, deep myometrial invasion, type 2 cancer). however, whether lymphadenectomy is required in patients with endometrioid endometrial cancers of grade 1 or 2 and with less than 50% myometrial invasion is controversial. then, the investigators conducted this prospective cohort study to investigate the efficacy of sentinel lymph node policy in patients with intermediate-risk endometrial carcinomas (grade 1 or 2, \< 50% myometrial invasion, and a tumor diameter ≥ 2 cm) as well as their outcomes. surgery should be performed within a maximum of 4 weeks from the patient's first consultation.

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years. 2. no contraindication to surgery. 3. signed and dated informed consent. 4. intermediate-risk endometrioid cancer with grade 1-2, superficial myometrial invasion and tumor diameter ≥ 2cm (in intraoperative frozen section examinations). 5. without any suspicious pelvic, paraaortic or distant lymph node metastasis in preoperative imaging tests including mri/ct/pet-ct. exclusion criteria: 1. low-risk endometrioid cancer with grade 1-2, superficial myometrial invasion and tumor diameter \< 2cm (in intraoperative frozen section examinations). 2. grade 3 endometrioid cancer (in preoperative pathological diagnosis or in intraoperative frozen section examinations). 3. deep muscular infiltration (in intraoperative frozen section examinations). 4. cervical invasion and/or ovarian/tubal invasion (in intraoperative frozen section examinations). 5. with suspicious pelvic, paraaortic or distant lymph node metastasis in preoperative imaging tests including mri/ct/pet-ct.

Keywords: sentinel lymph node policy
comparison of conventional free gingival grafts with partially de-epithelized free gingival grafts

Conditions: Gingival Recession

Summary: in this study, the conventional sdg method applied to increase the adherent gingival band and partial de-epithelialized sdg methods were evaluated in terms of aesthetics and color compatibility of the recipient area with adjacent tissues. this study is a controlled double-blind clinical trial randomized by split-mouth, envelope method.clinical parameters and aesthetic harmony were compared at postoperative 1st, 3rd and 6th months after surgical procedures.color harmony evaluation was made in 2 different ways, both by photo analysis of a blind researcher using computer software and by visual evaluation of the same blind researcher.

the primary aim of this split mouth randomized controlled clinical trial is to compare the partial de-epithelialized free gingival grafting technique with the conventional free gingival grafting technique from an aesthetic point of view. the secondary aim of the study is to evaluate both techniques in terms of periodontal clinical parameters. this study is a controlled double-blind clinical trial randomized by split-mouth, envelope method. fifteen patients with attached gingiva width ≤2 mm in the lower jaw bilateral canine and premolar regions were included in the study. de-epithelialized free gingival grafts were applied to the region determined by envelope randomization, and conventional free gingival grafts were applied to the other region. the areas of the patients with insufficient attached gingiva were photographed before the operation, post-op 1st, 3rd, and 6th months, and visual aesthetic evaluations were made with photo analyzes. clinical parameters such as keratinized gingival width, probing pocket depth, and recession depths were recorded at baseline and at 6 months. results were represented as mean ± standard deviation and median, and a p value of \<0,05 was considered statistically significant.

Eligibility criteria:
inclusion criteria: * absence of known systemic disease * not using any medication that may affect the periodontal tissues or prolong the bleeding time * having not previously operated on the palate area, which is both the receiving area and the donor area. * the depth of the probing sulcus of all teeth is \<3 mm * whole mouth plaque index and gingival index scores \<1 * the teeth in the operation area are vital * absence of caries and / or restoration on the root surfaces of the teeth in the operation area * lack of attached gingiva in opposite jaws exclusion criteria: * pregnant or lactating women, * smoking individuals, * individuals under the age of 18

Keywords: partial de-epithelialized free gingival graft
influence of metabolic syndrome on endogenous oxalate synthesis

Conditions: MASLD; Metabolic Dysfunction-Associated Steatotic Liver Disease

Summary: this study aims to determine the daily rate of endogenous synthesis of oxalate using fasted urine collection and a low-oxalate controlled diet in patients with metabolic dysfunction-associated steatotic liver disease (masld).

urinary oxalate excretion is derived from both dietary sources and endogenous synthesis. this study will use a low-oxalate controlled diet, repeat fasted urine collections and 24-hr urine collections on a low-oxalate diet, to determine the daily rate of endogenous oxalate synthesis in individuals with metabolic dysfunction-associated steatotic liver disease (masld).

Eligibility criteria:
inclusion criteria: * age \>18 years * history of masld, with liver fat content \> 5% * normal kidney function * stable medication for at least 1 month for diabetes mellitus if any * willingess to ingest fixed diets and stop dietary supplements for the study and come to uab for visits exclusion criteria: * age \< 18 years * inaccurate 24-hour urine collections * liver fat content \<5% * liver cirrhosis * evidence of other chronic liver disease, viral hepatitis * history of alcoholism within 2 years of enrollment * contra-indication to magnetic resonance imaging * chronic kidney disease with estimated glomerular filtration rate \< 60 ml/min/1.73m2 * type 1 diabetes mellitus or treatment with insulin * uncontrolled diabetes * pregnancy, lactation or intention to be * uncontrolled hypertension * use of weight loss medication, sglt2 inhibitors, glp-1 receptor agonists, osteoporosis medication, chronic nsaid * history of gastric or intestinal surgery or resection that could potentially alter oxalate absorption * chronic fat malabsorption * use of immunosuppressive medications * known immuno-compromised status * active malignancy or treatment for malignanacy within the last 12 months

Keywords: oxalate synthesis oxalate metabolism masld
prep affect regulation treatment innovation

Conditions: Medication Adherence; HIV Prevention; Stimulant Use

Summary: this multi-site randomized controlled trial enrolling sexual minority men who use stimulants and are currently taking pre-exposure prophylaxis (prep). this randomized controlled trial will test the efficacy of a prep affect regulation treatment innovation (parti) condition comprised of a 5-session positive affect intervention delivered during smartphone-based contingency management (cm) for directly observed prep doses (parti+cm) compared to an attention-control condition delivered during cm. the primary outcome is hiv acquisition risk measured using a combination of tenofovir-diphosphate levels in dried blood spots that are indicative of sub-optimal adherence to prep and recent condomless anal sex.


Eligibility criteria:
inclusion criteria: * assigned male at birth * identifies as male * age 18 or older * reads and speaks english * reports condomless anal sex (cas) with men in the past 6 months * self-reported hiv negative * active prescription for daily oral prep for at least 2 months and reports any non-adherence in the past month or initiated daily oral prep in the past 2 months, regardless of self-reported adherence * has an iphone or android smartphone * screens positive for a moderate or severe stimulant use disorder with an abbreviated version of the alcohol, smoking, and substance involvement screening test (assist; total score of 4 or more) or reports using stimulants at least weekly in the past 3 months. * lives in california or florida with no plans to move out of state in the next 6 months exclusion criteria: * unable or unwilling to provide informed consent * unwilling to upload upload 3 video recordings of directly observed prep doses using a smartphone application * identifies as transfeminine (e.g., transgender woman) * unable or unwilling to provide dried blood spot (dbs) specimen at baseline * switched from daily oral prep with disoproxil fumarate (tdf) to daily oral prep with tenofovir alafenamide (taf) in the past 5 months

Keywords: sexual minority men hiv prep adherence contingency management
chinese network of pediatric antiretroviral therapy

Conditions: Acquired Immunodeficiency Syndrome

Summary: this is an observational cohort in pediatric hiv patients in china. children who receive antiretroviral drugs will be recruited in this study. the main objectives are as follows: 1. to establish simpler and smarter pediatric antiretroviral therapy in china including both first-line and second-line regimens. 2. to study the nature, characteristics and mechanisms of immunoreconstitution in hiv-infected children using the data and samples from the pediatric antiretroviral therapy cohort. 3. to establish a basic science and clinical research network based on the pediatric antiretroviral cohort.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of hiv infection * receiving triple antiretroviral drugs exclusion criteria: * clinical status not stable

Keywords: children acquired immunodeficiency syndrome antiretroviral therapy china mortality
doxorubicin hydrochloride liposome injection combination with cyclophosphamide vs pirarubicin combination with cyclophosphamide in patients with locally advanced breast cancer

Conditions: Breast Cancer

Summary: evaluate the efficacy and safety of doxorubicin hydrochloride liposome injection plus cyclophosphamide compared to pirarubicin plus cyclophosphamide as neoadjuvant chemotherapy in locally advanced breast cancer patients


Eligibility criteria:
inclusion criteria: * female patients with age between 18 and 70 years. * newly diagnosed breast cancer, stages iib-iiic. * kps performance status≥70. * measurable disease according to recist version 1.1. * normal cardiac function confirmed by baseline left ventricular ejection fraction (lvef)≥50%. * adequate bone marrow reserve (wbc≥4.0×10(9)/l, neutrophils≥2.0×10(9)/l, platelets≥100×10(9)/l,and hemoglobin≥90g/l). * adequate hepatic and renal function. * ast and alt ≤ 2×institutional upper limit of normal；alkaline phosphatase ≤ 2×institutional upper limit of normal；bilirubin ≤ institutional upper limit of normal. * serum creatinine≥44 µmol/l and ≤133 µmol/l. * written informed consent are acquired. * not in pregnancy or the pregnancy tests of females is negative. exclusion criteria: * severe heart failure (nyha grade ii or higher). * active and uncontrolled severe infection. * have accepted any other anti-tumor drug within 30 days before the first dose or * received radiation treatment. * other situations that investigators consider as contra-indication for this study.
pillsense system for detecting ugi bleed

Conditions: UGI Bleed; Upper Gastrointestinal Bleeding; Upper Gastrointestinal Bleed

Summary: this is a prospective, non-randomized, open-label clinical investigation to evaluate feasibility, effectiveness and safety of the pillsense system, the transit of the pillsense capsule through the gi tract, patient tolerability of the pillsense capsule, and blood detection.

patient eligibility as set out in the inclusion/exclusion criteria for the clinical investigation will be reviewed prior to study enrollment. prior to administering the pillsense capsule, the pillsense receiver will be paired with the pillsense capsule. the pillsense receiver collects and displays real-time information gathered by the pillsense capsule. the pillsense receiver interprets the data and displays a result message "blood detected" or "no blood detected". the overall investigation from the pillsense capsule activation and ingestion until the result message is displayed takes less than 10 minutes. esophagogastroduodenoscopy (egd) should be completed immediately or up to 4 hours after pillsense capsule administration in each patient that receives a "blood detected" or "no blood detected" result to confirm the result achieved with the pillsense system. the endoscopy will be conducted according to the site's standard of care. prior to discharge each patient will undergo an x-ray examination to evaluate for pillsense capsule presence. following discharge, if there is no verifiable evidence that the pillsense capsule passed through the gastrointestinal tract (git) (such as a photograph of stool with capsule in it or photograph of the capsule alone), the patient may undergo an x-ray examination at day 7 ± 5 days and, if necessary, at day 14± 7 days to ascertain the passage status of the pillsense capsule. if the pillsense capsule did not pass through the git, it should be removed by an endoscopic method.

Eligibility criteria:
inclusion criteria * age \>=18 years * ability to provide informed consent * clinical suspicion of ugib exclusion criteria: * circulatory or hemodynamic instability * known gi tract stricture * using an implantable electrical device * difficulties in swallowing pills the size of the capsule * history of: achalasia or known esophageal dysmotility; gastroparesis; severe constipation; crohn's disease; bowel obstruction * currently taking medications intended for stimulation of gi motility * currently pregnant or breastfeeding, or intend to become pregnant during the investigation * suspected or previously diagnosed obstructing gastrointestinal tumor

Keywords: enterasense pillsense ugi bleed ugib upper gastrointestinal bleeding upper gastrointestinal bleed upper gastrointestinal